OBJECTIVES. To report the results of a modified vaporisation incision technique using a GreenLight High Performance System in the treatment of benign prostatic disease in men receiving anticoagulants.

DESIGN. Case series.

SETTING. Regional hospital, Hong Kong.

PATIENTS. From January 2007 to April 2010, 48 patients with a bleeding tendency or on oral anticoagulants who underwent photoselective vaporisation prostatectomy with a GreenLight High Performance System in the North District Hospital were studied. Data collected prospectively were analysed to determine perioperative and postoperative outcomes, including uroflowmetry parameters, serum prostate-specific antigen level, prostate volume, and complications at 1, 3, 6, and 12 months post-surgery.

RESULTS. The patients' mean age was 76 (standard deviation, 7; range 62-94) years. The mean follow-up period was 13 (standard deviation, 9) months. Thirty-six (75%) patients had urinary retention prior to surgery. Bleeding tendencies were due to receipt of aspirin (n=36), two antiplatelet agents (n=6), warfarin (n=4) and clopidogrel (n=1), and to thrombocytopaenia (n=1). Preoperative transrectal ultrasonography showed a mean prostate size of 58 (standard deviation, 30; range, 18-154) mL. Of the patients, 81% were discharged without a catheter and their mean hospital stay was 3 days. Five patients were readmitted for secondary haemorrhage, two had a drop of more than 10 g/L in their haemoglobin level, but only one received a blood transfusion. Mean uroflowmetry parameters, namely, peak flow rate and residual volume, were 8.7 mL/s and 199 mL preoperatively and 14.7 mL/s and 50 mL 1 year after the operation.

CONCLUSION. With an ageing population in which patients with various co-morbidities receive anticoagulant/antiplatelet therapy, photoselective vaporisation prostatectomy using a GreenLight High Performance System is a safe treatment option.

Key words: Laser therapy; Prostate-specific antigen; Prostatectomy; Prostatic hyperplasia; Treatment outcome

View this abstract indexed in MEDLINE:

OBJECTIVES. To report the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor and the safety profile of multiple doses of bevacizumab from the same vial reused for multiple patients.

DESIGN. Case series.

SETTING. A private hospital in Hong Kong.

PATIENTS. A systematic retrospective review of consecutive intravitreal anti-vascular endothelial growth factor injections between 5 June 2006 and 17 December 2010 at a single institute was conducted. Patients were identified from prospectively designed audit forms, and each patient's medical record was reviewed for any documented complications. Bevacizumab 1.25 mg/0.05 mL to 2.50 mg/0.1 mL was aspirated from the designated vial, with a maximum of 10 consecutive injections being aspirated from the same vial. The opened vial was then discarded without overnight storage. Ranibizumab was aspirated from the commercially available 1 mg/0.1 mL single-use vial.

RESULTS. A total of 1655 intravitreal anti-vascular endothelial growth factor injections into 392 eyes of 383 patients were evaluated during the study period. There were 1184 bevacizumab injections and 471 ranibizumab injections. There was one case of suspected endophthalmitis after ranibizumab injection, though culture of the vitreous tap was negative. The point prevalence of endophthalmitis was 0.06% (1/1655) for the total number of injections: 0.21% (1/471) after ranibizumab, and 0% after bevacizumab.

CONCLUSION. Although many centres aliquot multiple syringes from a single vial to be kept in a refrigerator for use, the current study shows that so long as proper sterile techniques are implemented, there were no cases of endophthalmitis from using the same vial, which was reused for a maximum of 10 consecutive injections. For intravitreal injection, bevacizumab costs approximately US$50 to US$100 per dose, as opposed to US$2000 per dose for ranibizumab. Sharing multiple doses of bevacizumab from a single vial can substantially reduce the cost of treatment.

Key words: Endophthalmitis; Intravitreal Injections; Ranibizumab; Receptors, Vascular endothelial growth factor; Bevacizumab

View this abstract indexed in MEDLINE:

OBJECTIVES. To identify prognostic factors in children receiving continuous renal replacement therapy.

DESIGN. Historical cohort study.

SETTING. Neonatal and paediatric intensive care unit of a Hong Kong hospital.

PATIENTS. Neonatal or paediatric patients who received continuous renal replacement therapy from January 1998 to December 2008.

RESULTS. In all, 37 patients who received 39 episodes of continuous renal replacement therapy were identified. The male-to-female ratio was 1.5:1. Among the 39 episodes, 15 (39%) were performed on neonates with a mean birth weight of 2.6 (standard deviation, 0.7; range, 0.9-3.7) kg, and 24 (62%) were performed on paediatric patients with a mean age of 7.9 years (standard deviation, 6.4 years; range, 6 months to 18 years). The overall mortality was 41%; in the neonatal and paediatric groups it was 60% and 29%, respectively. There was no significant difference in the mean and maximal ultrafiltration rate in survivors and non-survivors. Multivariate analysis identified the PRISM III score and fluid overload as independent predictors of mortality. Kaplan-Meier survival analysis showed that patients with pre-continuous renal replacement therapy fluid overload of 5.5% or more was associated with reduced survival in the intensive care unit as compared to those having less severe fluid overload (P=0.011). In neonatal patients, there was a higher proportion with multi-organ failure and severe fluid overload.

CONCLUSION. High PRISM III scores and the degree of pre-continuous renal replacement therapy fluid overload were independent predictors of mortality.

Key words: Acute kidney injury; Child; Renal dialysis; Renal replacement therapy

View this abstract indexed in MEDLINE:

OBJECTIVE. To establish and verify the utility of measuring urine prostate cancer antigen 3 (PCA3) mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients.

DESIGN. Cross-sectional study.

SETTING. Urology Unit of a regional hospital in Hong Kong.

PATIENTS. This study was carried out in two parts. In the first part, 102 post-prostatic massage urine samples were collected from patients with known prostate cancer (38 patients) and controls (64 patients, with normal digital rectal examination and serum prostate-specific antigen <4 ng/mL). The urine levels of PCA3 and prostate-specific antigen mRNA were measured and the best cut-off point for differentiating cancer was determined. In the second part of the study, post-prostatic massage urine samples from 47 patients with clinically suspected prostate cancer were collected prior to prostate biopsy. The performance of PCA3 as a diagnostic aid for cancer was then assessed using the aforementioned cut-off value.

RESULTS. In the first part of the study, the best cut-off for the PCA3 ratio (defined as the ratio of the Ct value of PCA3/PSA mRNA) was 1.127. Applying this cut-off to the 47 patients with clinically suspected prostate cancer and no history of previous prostate biopsy, the sensitivity and specificity of PCA3 for diagnosing prostate cancer were 71% and 92%, respectively.

CONCLUSION. The post-prostatic massage urine PCA3 level shows utility for diagnosing prostate cancer in patients with elevated prostate-specific antigen levels that could facilitate decisions to undertake prostate biopsy and avoid unnecessary biopsies.

Key words: Predictive value of tests; Prostate-specific antigen; Prostatic neoplasms; RNA, messenger; ROC curve

View this abstract indexed in MEDLINE:

OBJECTIVES. To clarify the use of ultrasonography by determining the frequency of developmental dysplasia of the hip among breech-presented Chinese neonates in Hong Kong.

DESIGN. Prospective case series.

SETTING. Regional hospital, Hong Kong.

PATIENTS. All breech-presented Chinese neonates born during January 2008 to June 2009 were included (except premature neonates). They were examined clinically from birth till the age of 1 year. Ultrasound of the hips was performed at the age of 2 weeks, and X-ray of the pelvis at the age of 1 year.

RESULTS. A total of 209 breech-presented neonates were born during the study period; 110 neonates completed all necessary investigations and follow-up. Among the latter, there were three neonates with developmental dysplasia of the hip warranting treatment, which amounted to a frequency of 2.7%.

CONCLUSION. Developmental dysplasia of the hip among breech-presented Chinese babies is only slightly less common than in corresponding populations in other regions in the world. Since early diagnosis is important, ultrasonography screening in high-risk cases such as those with breech presentation may be useful.

Key words: Breech presentation; Hip dislocation, congenital; Hong Kong; Incidence

View this abstract indexed in MEDLINE: